Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Was Celgene’s Third Quarter Really Crash-Worthy?

TheMotleyFool

0 0

Was Celgene’s Third Quarter Really Crash-Worthy?

On the heels of reporting a disappointing late-stage trial failure, Celgene Corp. (NASDAQ: CELG) issued a poor third-quarter financial report that's stoking investors' fears. Has the biotech lost its golden touch, or is it a bargain-bin buy in the making?

Celgene is one of the world's biggest biotech companies. Its track-record includes successfully developing and commercializing four billion-dollar-plus blockbuster drugs: Revlimid, Pomalyst, Otezla, and Abraxane.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com